{"id":482823,"date":"2021-04-27T16:33:28","date_gmt":"2021-04-27T20:33:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/"},"modified":"2021-04-27T16:33:28","modified_gmt":"2021-04-27T20:33:28","slug":"adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/","title":{"rendered":"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PHILADELPHIA and OXFORDSHIRE, United Kingdom, April  27, 2021  (GLOBE NEWSWIRE) &#8212; Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference.<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Abstract Title:<\/strong><br \/>\n          <em>In vitro<\/em> selection and engineering of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin (Abstract # 641)<\/li>\n<li>\n          <strong>Poster Presentation: <\/strong>Tuesday May 11, 2021 8:00 a.m. &#8211; 10:00 a.m. EDT during the Cancer &#8211; Immunotherapy, Cancer Vaccines Session<\/li>\n<\/ul>\n<p>\n        <strong>About Adaptimmune<\/strong><br \/>\n        <br \/>Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company\u2019s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.<\/p>\n<p>\n        <strong>Adaptimmune Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Media Relations:<\/strong>\n      <\/p>\n<p>S\u00e9bastien Desprez \u2014 VP, Communications and Investor Relations<br \/>T: +44 1235 430 583<br \/>M: +44 7718 453 176<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SB_Zi1iYZpEcz8drCBjc9mbPkMzq1cH9EFUQBDfr1-ytCTll3fdzXzTk6NbipKWj2iAdIjDkyRMvw1NaLptn6VKJsqxPLVsj2L5NxImyLVCCAUm43-NuO_U3McW1ru5Z\" rel=\"nofollow noopener\" target=\"_blank\">Sebastien.Desprez@adaptimmune.com<\/a><\/p>\n<p>\n        <strong>Investor Relations:<\/strong>\n      <\/p>\n<p>Juli P. Miller, Ph.D. \u2014 Senior Director, Investor Relations<br \/>T: +1 215 825 9310<br \/>M: +1 215 460 8920<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5KVBCb5b4Z2TNxyKZc_p0-UUzX4qc6A73AuO9eNYtl6H84KN50HXgfv7FkxzbLOif3fRyYzO23Vc0uI8y6VM5U6iEr-iXrTDDlxdkVpxcP539Dqbm4CTCeRh0I5d7k32\" rel=\"nofollow noopener\" target=\"_blank\">Juli.Miller@adaptimmune.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5e4dce57-1ccb-485c-9efe-5eecf2e3cfae\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) &#8212; Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference. Abstract Title: In vitro selection and engineering of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin (Abstract # 641) Poster Presentation: Tuesday May 11, 2021 8:00 a.m. &#8211; 10:00 a.m. EDT during the Cancer &#8211; Immunotherapy, Cancer Vaccines Session About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-482823","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) &#8212; Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference. Abstract Title: In vitro selection and engineering of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin (Abstract # 641) Poster Presentation: Tuesday May 11, 2021 8:00 a.m. &#8211; 10:00 a.m. EDT during the Cancer &#8211; Immunotherapy, Cancer Vaccines Session About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development &hellip; Continue reading &quot;Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T20:33:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT\",\"datePublished\":\"2021-04-27T20:33:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/\"},\"wordCount\":372,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/\",\"name\":\"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=\",\"datePublished\":\"2021-04-27T20:33:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/","og_locale":"en_US","og_type":"article","og_title":"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT - Market Newsdesk","og_description":"PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) &#8212; Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference. Abstract Title: In vitro selection and engineering of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin (Abstract # 641) Poster Presentation: Tuesday May 11, 2021 8:00 a.m. &#8211; 10:00 a.m. EDT during the Cancer &#8211; Immunotherapy, Cancer Vaccines Session About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development &hellip; Continue reading \"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-27T20:33:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT","datePublished":"2021-04-27T20:33:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/"},"wordCount":372,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/","name":"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=","datePublished":"2021-04-27T20:33:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDI1MiM0MTQwNzkwIzIwMTg3NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit-platform-at-asgct\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=482823"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482823\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=482823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=482823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=482823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}